Skip to search formSkip to main contentSkip to account menu

BYM338

Known as: HuCAL-based Antibody BYM338, Human Combinatorial Antibody Library-based Monoclonal Antibody BYM338 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bimagrumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data].
A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin… 
2017
2017
Novartis antibody increases muscle growth in mice and human cell cultures
  • 2017
  • Corpus ID: 44484613
“This study illustrates that we have the potential to prevent muscle wasting and promote muscle growth in cell and animal models… 
2016
2016
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?
Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by… 
Review
2014
Review
2014
Phase II drugs that are currently in development for the treatment of cachexia
Introduction: Cachexia is a syndrome presenting with progressive unintentional weight loss and wasting and weakness of skeletal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)